💊All about MEDROXYPROGESTERONE acetate medicine: medroxyprogesterone dosage (5mg, 10mg, 150 mg), medroxyprogesterone uses, medroxyprogesterone side effects, medroxyprogesterone contraindications, medroxyprogesterone interactions, medroxyprogesterone mechanism of action (moa).
Hello welcome to my channel subscribe or like if you like today we are going to talk about the medicine medroxyprogesterone we will answer questions such as what is medroxyprogesterone what is medroxyprogesterone for and we will also explain its mechanism of action side effects dosage uses contra indications warnings pregnancy and indications the commercial names
Of majroxy medroxyprogesterone are depo provera provera curitab mechanism of action of medroxyprogesterone anti-estrogenic anti-androgenic and anti-gonadotropic action inhibits the secretion of pituitary gonadotrophin with the consequent inhibition of follicular maturation and ovulation what is medroxyprogesterone used for the therapeutic indications and dosage
Of medroxyprogesterone are one doctoral treatment in adults co-adjuvant treatment to estrogenic therapy in non-hysterectomized menopausal women 5 to 10 milligrams per day last 10 to 14 days of estrogenic therapy secondary amenorrhea 2.5 to 10 milligrams per day 5 to 6 days start day 16 or 21 of the cycle patients with endometrial atrophy associate in estrogen
Functional menometroragia 2.5 to 10 milligrams per day 5 to 10 days start day 16 or 21 of the cycle once blood loss is controlled repeat two consecutive cycles sterility from 2.5 to 10 milligrams per day starting on the second half of the cycle pre-menstrual tension from 2.5 to 10 milligrams per day five to seven days before the end of the cycle dysmenorrhea from
2.5 to 10 milligrams per day from day 5 to 25 of the cycle endometriosis 10 milligrams every 8 hours from day 1 of the cycle 90 consecutive days deep intramuscular treatment in adults contraception 150 milligrams administered within the first five days of the menstrual cycle every three months co-adjuvant therapy of an operative recurrent and metastatic endometrial
Carcinoma initial dose of 400 to 1000 milligrams per week maintenance lower doses of 400 milligrams per month medroxyprogesterone contra indications hypersensitivity thrombophlebitis and thromboembolic phenomena severe hypertension severe liver failure abnormal uterine bleeding metroragia and menorrhagia or undiagnosed urinary tract bleeding delayed abortion
Pregnancy suspicion or evidence of hormone-dependent breast or genital organ malignancy medroxyprogesterone warnings and precautions high blood pressure history of migraine or unusual severe headaches acute visual disturbances diabetes history of endogenous depression may cause fluid retention aggravating illness in patients with a history of epilepsy migraines
Asthma liver or kidney failure heart disorders perform blood tests or medical examinations every six months control in cases of severe depression and history of myocardial or cerebral infarction interrupt treatment effects ophthalmia diplopia thromboembolic disorders are present may produce loss of bone mineral density menstrual irregularities weight gain may
Increase the risk of breast cancer liver failure and medroxyprogesterone contraindicated in severe liver failure caution in liver failure kidney failure and medroxyprogesterone caution interactions with medroxyprogesterone efficacy diminished by aminoglutathiomide diminished efficacy of hypoglycemics and oral anticoagulants pregnancy and medroxyprogesterone contra
Indicated it has been pointed out a possible relationship between the administration of progestins in the first months of pregnancy and the presence of congenital malformations in the newborn taking into account this circumstance and the risk of virilization in female fetuses the patient should be informed of the potential risk to the fetus children accidentally
Gestated during the first two months after intramuscular injection may present an increased risk of low birth weight which is in turn associated with an increased risk of neonatal death in animal studies medroxyprogesterone acetate has been shown not to be teratogenic mutagenic or carcinogenic beagle dogs treated with medroxyprogesterone acetate developed mammary
Nodules some of which were malignant in nature although nodules occasionally appeared in control animals they were intermittent in nature while nodules in treated animals were larger more numerous persistent and some malignant causing breast cancer and metastasis the meaning of this fact with respect to man has not been established lactation and medroxyprogesterone
Progestogens have been detected in breast milk and although their effect on the infant is unknown as a general rule breastfeeding should be avoided side effects and adverse reactions of medroxyprogesterone vaginitis nervousness anorgasmi or decreased libido depression insomnia headache dizziness hot flashes abdominal pain or discomfort nausea skin rash alopecia
Or lack of hair growth acne back pain leg cramps menstrual irregularities bleeding and aramenria pelvic pain breast pain leukeria asthenia weight changes edema swelling
Transcribed from video
Medroxyprogesterone SIDE EFFECTS | Medroxyprogesterone DOSAGE | Medroxyprogesterone Acetate USES By Medicines/Diseases
